Corcept Therapeutics Incorporated Company Profile
Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. Its products include Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing mifepristone, Korlyms active ingredient, which is in Phase I/II clinical trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with metastatic, triple-negative breast cancer, a form of solid-tumor cancer with a particularly poor prognosis; and CORT125134 that is in Phase I clinical trials for the treatment of patients with Cushings syndrome and solid-tumor cancers. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.